[Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega
R
R
Unitat d'Hepatologia, Institut de Malalties Digestives, Hospital Clínic, Barcelona.
Calahorra
B
B
Ginès
P
P
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006530:Hepatorenal Syndrome / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology; D008236:Lypressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008879:Midodrine / Q000008:administration & dosage / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D009951:Ornipressin / Q000627:therapeutic use; D010865:Pilot Projects; D012079:Renal Circulation / Q000187:drug effects; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D000418:Albumins; D014662:Vasoconstrictor Agents; D009951:Ornipressin; D008236:Lypressin; D008879:Midodrine; D000077585:Terlipressin; D015282:Octreotide